Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C152948
http://purl.obolibrary.org/obo/NCIT_C152948
|
|---|---|
| Preferred Name | Zenocutuzumab |
| Definitions |
A full-length IgG1 bispecific antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) directed against human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and human epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic activity. Upon intravenous administration of zenocutuzumab, the bispecific antibody docks on HER2, and subsequently blocks heregulin-stimulated proliferation of tumor cells by binding HER3. In addition to inhibiting HER3-dependent signaling, simultaneous targeting of HER2 and HER3 by zenocutuzumab may overcome a common resistance mechanism driven by heregulin-mediated dimerization of HER2 and HER3. Zenocutuzumab is expected to eliminate tumor cells by recruiting natural killer (NK) cells to tumor cells coated with the bispecific antibody.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A full-length IgG1 bispecific antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) directed against human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and human epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic activity. Upon intravenous administration of zenocutuzumab, the bispecific antibody docks on HER2, and subsequently blocks heregulin-stimulated proliferation of tumor cells by binding HER3. In addition to inhibiting HER3-dependent signaling, simultaneous targeting of HER2 and HER3 by zenocutuzumab may overcome a common resistance mechanism driven by heregulin-mediated dimerization of HER2 and HER3. Zenocutuzumab is expected to eliminate tumor cells by recruiting natural killer (NK) cells to tumor cells coated with the bispecific antibody. |
|---|---|
| prefLabel | Zenocutuzumab
|
| label | Zenocutuzumab
|
| NCI_META_CUI | CL554279
|
| PDQ_Closed_Trial_Search_ID | 794043
|
| code | C152948
|
| Has_Target | |
| prefixIRI | NCIT:C152948
|
| in_subset |
See more
See less
|
| Display_Name | Zenocutuzumab
|
| Preferred_Name | Zenocutuzumab
|
| FDA_UNII_Code | AE72RB1W1X
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128
|
| CAS_Registry | 1969309-56-5
|
| NCI_Drug_Dictionary_ID | 794043
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 794043
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |